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http://dx.doi.org/10.1016/j.pedneo.2Objectives: The usual initial dose of prostaglandin E1 (PGE1) for ductal-dependent congenital
heart disease (CHD) is 50e100 ng/kg/minute. The aim of this study was to review our experi-
ence of a low initial dose of PGE1 treatment in early newborns with congenital heart disease
and patent ductus arteriosus (PDA)-dependent pulmonary flow.
Methods: We reviewed the clinical data of 33 newborns with CHD and PDA-dependent pulmo-
nary circulation who were admitted from January 2005 to December 2010. Clinical parameters
were collected, including, PGE1 dosage, oxygenation condition, vital signs, and other related
clinical parameters during admission. Echocardiography was employed to assess the status of
the PDA as clinically indicated.
Results: Thirty-three newborns, including 17 males and 16 females, with CHD and PDA-
dependent pulmonary circulation were enrolled in the study. Their mean age was 2.9  5.1
(within the range of 1e26) days with a median of 1.0 day. Among the 33 cases, 25 were diag-
nosed with pulmonary atresia and eight with critical pulmonary stenosis. Twenty-five of our
patients were treated with the initial low-dosage regimen of 20.0  7.4 ng/kg/minute in
our neonatal intensive care unit. None of these 25 patients with had significant apnea neces-
sitating intubation and none had hypotension, fever, convulsion or cortical hyperostosis. Three
of the eight patients who were treated with high-dose PGE1 (39  13.2 ng/kg/minute) before
referral to our unit had apnea and intubation after PGE1 use. All patients had adequate PDA
patency with a low maintenance dose of 10.5  5.3 ng/kg/minute before operation under
our protocol.t of Pediatrics, Kaohsiung Veterans General Hospital, 386, Ta-Chung 1st Road, Kaohsiung, Taiwan
.tw (K.-S. Hsieh).
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Prostaglandin dose for ductus-dependent pulmonary circulation 103Conclusion: In our experience, adequate PDA flows in early newborns with CHD and PDA-
dependent pulmonary circulation could be achieved at a much lower dose than recommended
in the literature. The lower dose of PGE1 also causes much fewer complications, such as
apnea, fever, and hypotension. For early newborns with CHD and PDA-dependent pulmonary
circulation, treatment with a lower initial dose of PGE1 of 20 ng/kg/minute and a maintenance
dose of 10 ng/kg/minute is recommended.
Copyright ª 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Ductus arteriosus is a vessel vital for the fetal circulation1
that becomes unnecessary and usually closes within days
after birth.2e4 However, some infants with congenital heart
disease (CHD) rely on ductus arteriosus.5,6 To prevent the
patent ductus arteriosus (PDA) closure after birth, prosta-
glandin E1 (PGE1) has been routinely used for these
patients in intensive care units for more than 30 years.7
According to the literature, the usual initial dose of
PGE1 is around 50e100 ng/kg/minute to keep the ductus
arteriosus open8e13; however, such a high initial PGE1 dose
often results in side effects, such as fever, respiratory
distress, diarrhea, and apnea.14e16 To avoid these compli-
cations, we have titrated the PGE1 to a lower-dose regimen
for more than a decade. The purpose of this study was to
evaluate the application of the lower dose of PGE1 in
newborns with CHD and PDA-dependent pulmonary
circulation.Table 1 Type of coronary heart disease among the
patients.
Disease Number
PA þ TOF 8
TOF þ PS 3
PA þ IVS 5
Critical PS 2
PA þ CAVC 3
PA þ CAVC þ TAPVR 2
PA þ DORV 2
PS þ CAVC þ DORV 2
TOF þ PA þ VSD 2
PA þ SV 2
PA þ TA 1
Critical PS þ VSD 1
Total 33
ASD Z atrial septal defect; CAVC Z complete atrioventricular
canal; DORV Z double outlet right ventricle; IVS Z intact
ventricular septum; PA Z pulmonary atresia; PS Z pulmonary
stenosis; SV Z single ventricle; TA Z tricuspid atresia;
TAPVR Z total anomalous pulmonary venous return;
TOF Z tetralogy of Fallot; VSD Z ventricular septal defect.2. Materials and Methods
Our policy of administrating PGE1 therapy for newborns
with PDA-dependent CHD is that in the situation of aggra-
vating cyanosis compatible with impending closure in the
neonatal intensive care unit, an initial dose of 20 ng/kg/
minute of PGE1 is started. If there is no improvement in
oxygenation, stepwise dose increases of 5 ng/kg/minute
are administered until no further increase of oxygenation
occurs, or until pulse oximetry (SpO2) has reached the pre-
closure level of the ductus arteriosus. After stabilization for
about 1 day, the initial dose is gradually tapered to around
10 ng/kg/minute as maintenance to keep the PDA open.
We reviewed the clinical records of 33 newborns with
CHD with PDA-dependent pulmonary circulations who were
admitted to our hospital between January 2005 and
December 2010. We defined an intravenous dose of <30 ng/
kg/minute of PGE1 for initial re-opening of the PDA as low
dose, and a dose >30 ng/kg/minute as high-dose. We
analyzed the dose of PGE1, blood gas data (from umbilical
vein, central venous catheter or peripheral central venous
catheter, depending on the availability of the line), vital
signs, and their complications, etc. Echocardiography was
performed to assess the status and diameter of the PDA.
Continuous parameters were compared using the two-
tailed independent Student t test. Analyses of significance
were performed. A p value of <0.05 was considered to be
statistically significant.3. Results
During the study period, 33 newborns with CHD with PDA-
dependent pulmonary circulation were admitted to our
neonatal intensive care unit. The various congenital cardiac
defects of ductus-dependent pulmonary circulation are
shown in Table 1. Among the 33 newborns, 16 (48%) were
females and 17 (52%) were males. Twenty-five patients
(75%) had pulmonary atresia and the other eight patients
(25%) had pulmonary stenosis. The mean gestational age
was 37  2 weeks and the mean birth body weight was
2827  521 g. The mean age on starting PGE1 treatment
was at 3.3  5.8 (within the range of 1e26) days of age,
with a median of 1.0 day.
The initial lower-PGE1-dose regimen of 20.0  7.4 ng/
kg/minute (in the range of 10e30 ng/kg/minute) was used
in 25 patients whose intravenous PGE1 therapy started in
our neonatal intensive care unit. Before treatment, the
mean diameter of ductus arteriosus was 1.7  0.3 mm, as
measured by echocardiography. After treatment, the mean
ductus arteriosus diameter improved to 3.7  0.7 mm.
When the PDA was wide open, we gradually tapered the
mean maintenance dosage to 10.5  5.3 (within the range
of 5e20) ng/kg/minute. Their mean initial SpO2 was
Table 3 Side effects during lower-dose PGE1 treatment of
33 patients.
Symptoms Numbers (%)
Apnea 8 (24)
Intubation due to apnea 0 (0)
Fever 0 (0)
Convulsion 0 (0)
Hypotension 0 (0)
Cortical hyperostosis 0 (0)
Loose stool 2 (6)
Hemorrhagic diathesis 0 (0)
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26.48  6.45 mmHg. At the point when stable wide open
PDA (diameter of ductus arteriosus widens with unre-
stricted blood flow under echocardiography) was achieved,
their mean SpO2 increased to 85.33  7.92% (p < 0.05) and
mean venous PO2 of central vein blood gas increased to
40.85  9.56 mmHg, both with statistical significance
(Table 2).
For the other eight patients, an initial high dose regimen
of 39  13.2 (within the range of 30e70) ng/kg/minute was
employed. All eight patients had been transferred from
other hospitals and received PGE1 starting at 1.5  0.9
(within the range of 1e3) days of age with a median of 1.0
day before referral. There was no statistically significant
difference in age at starting PGE1 treatment between the
initial low- and high-dose groups.
Parameters such as vital signs, oxygen saturation,
oxygen concentration in blood gas and general activity
were monitored serially. During PGE1 treatment, eight of
the 33 newborns (24%) had apnea attacks. Among them,
five newborns were treated with low initial dose and three
newborns were treated with high initial dose before arrival.
Compared to the 25 patients receiving low initial PGE1
dosage who did not need intubation, three of the eight
newborns (37.5%) receiving a high initial PGE1 dosage
needed intubation before arrival from other hospitals due
to an unstable respiratory pattern. Concerning other
complications possibly related to PGE1 therapy, loose stool
occurred in two newborns (one in the high- and another in
the low-dose group). None of the 33 patients had other
complications such as fever, convulsion, or hypotension,
etc. (Table 3).
The only mortality before operation was one male
newborn who was born at gestational age of 40þ weeks,
with a birth body weight 2830 g and situs inversus, dex-
trocardia, common atrial-ventricular canal, pulmonary
atresia, severe atrioventricular valve regurgitation and
large PDA. He was initially administered 6e12 ng/kg/
minute of PGE1 under continuous infusion. Severe heart
failure due to atrioventricular valve regurgitation occurred
at 3 days of age. Emergent endotracheal tube intubation
was performed and large-dose inotropic agents were given.
His general condition deteriorated with severe metabolic
acidosis and desaturation with SpO2 of <70%, even under
ventilator support with FiO2 at 100%. The parents hesitated
over consenting to surgical repair and the baby expired 26
days after admission. Throughout the course the PDA was
wide open at a low maintenance dose. It is clear that the
severe atrioventricular valve regurgitation contributed to
the severe desaturation of the patient.Table 2 PGE1 dosage and treatment responses.
Initial Maintain p*
PGE1 (ng/kg/minute) 20.02  7.4 10.54  5.27 d
PO2 (mmHg) 26.48  6.45 40.85  9.56 <0.001
SpO2 (%) 69.32  9.01 85.33  7.92 <0.001
*p < 0.05 if compared with normal population by WHO standard.
PGE1 Z prostaglandin E-1; PO2 Z pressure of oxygen from
central vein blood gas.Except for the newborn (3%) who had been transferred
from another hospital and expired as described above,
there were no mortalities related to PGE1 use in our series.
All the other 32 newborns had stable opening PDA and
bridged smoothly to surgical intervention.4. Discussion
PGE1 was first noted as a potent relaxant of the ductus
arteriosus in 1973 and it has been used to keep the ductus
arteriosus open for decades.17 It was approved in 1981 by
the Food and Drug Administration (FDA) in the United
States. There were numerous reports about its side effects
under the current dosage schedule,7,9e12,17 such as apnea,
fever, hypotension, and diarrhea which increased with
increasing dosages of PGE1.14,15,18e23
As mentioned above, higher PGE1 dosages cause many
complications. However, the current recommended dose
for PGE1 use has remained at 50e100 ng/kg/minute, and
surprisingly there has been no change in this dose recom-
mendation since its first introduction into clinical
use.8,10e14 We have titrated the dosage in our neonatal
intensive care unit for over a decade with an initial dosage
at around 20 ng/kg/minute and a maintenance dosage of
around 10 ng/kg/minute. In addition to the conventional
clinical parameters, we also used echocardiography to
provide useful information about the effect of PGE1 on the
patency of the ductus arteriosus. Our patients showed
a universally good response to low-dose PGE1 infusion. Our
experience also showed that the initial low PGE1 dose could
be further tapered down to around 10 ng/kg/minute once
a stable oxygenation condition has been achieved.
In our patients, the PO2 data was obtained from central
vein gas (umbilical vein or central vein) because this is safe
and convenient for newborn patients. It was very difficult
to set up an arterial line under unstable conditions and
some reports had supported the assertion that central
venous blood gas values may be an acceptable way to
provide the information.24,25 Despite this, the venous PO2
also improved significantly under lower initial PGE1 dose.
The dosage of PGE1 and duration of its use are considered
to relate to the side effects.22,26 In our patients given a lower
initial dosage, the incidences of side effects due to PGE1
(such as apnea, fever, convulsion, hypotension and diarrhea)
were all lower than the reported series.14,20e23,27e30
In particular, only five newborns (20%) given the lower
initial PGE1 dose had apnea attacks; all the apnea attacks
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none needing intubation. This was less than the three
newborns who were initially given a high initial dose at the
referral hospital (37.5%). Since apnea is an important
complication related to PGE1 use, our low dose of PGE1
appears very beneficial.
Kramer et al.29 suggested that a low dose of PGE1 infu-
sion at an initial dose of <10 ng/kg/minute could result in
less apnea. However, in the patient group, very few (12/91)
patients were given a initial dose of PGE1 of <20 ng/kg/
minute, which means that a small percentage of patients
could have their PDA open with PGE at a dose of <20 ng/kg/
minute. Our past experience showed the same tendency
and thus we chose the initial dose of 20 ng/kg/minute of
PGE1 as our low-dose policy.
In our experience, the duration of PGE1 treatment before
the cardiac surgery was 11.24 6.24 days. If newborns were
treated with PGE1 for longer than 2 weeks, fluid electrolyte,
digestion and other clinical conditions should be monitored
closely.22,23,26 Recently, there have been reports of stent
implantation in the ductus arteriosus for pulmonary or
systemic circulation.31e33 However, the morphology of the
ductus arteriosus, clinical conditions and operators’ expe-
riences influence the outcome of the procedures.33 Before
the Blalock-Taussig shunt or other corrective operation on
these newborns,34e37 PGE1 treatment is still a reliable
method for short-term bridging before surgery.
5. Study Limitations
There were some limitations in our study. It was based
solely on the information from chart reviews and some
record bias exists in the results. The number of cases was
relatively small. However, due to the declining birthrate in
Taiwan,6 large case series are a challenge. The mean age of
initial PGE1 dose was also <2 weeks (median 1 day), both in
the high- and low-dose groups. Thus, bias may exist
regarding the effects on those older newborns. We believe
our unique experience can provide useful information
about a low initial dose of PGE1 in early newborns with CHD
and ductus-dependent pulmonary blood flow.
6. Conclusion
Careful titration with a lower initial dose of 20 ng/kg/
minute rather than 100 ng/kg/minute or 50e100 ng/kg/
minute7e9,12 and rapid tapering to a maintenance dosage of
PGE1 at 10 ng/kg/minute is effective to keep the ductus
arteriosus open, with fewer side effects.7e9,12 Our low
initial dose is only 25e50% of the conventional dose. We
expect wide application of low-dose PGE1 in early
newborns with critical CHD and PDA-dependent pulmonary
circulation in the future. An additional study is now being
undertaken to enroll more cases of various critical CHDs
with ductal-dependent systemic circulation.
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